nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Coxalgia—Lisinopril—dilated cardiomyopathy	0.0481	0.0704	CcSEcCtD
Etoricoxib—Vemurafenib—RAF1—dilated cardiomyopathy	0.0358	1	CrCbGaD
Etoricoxib—Breast cancer—Spironolactone—dilated cardiomyopathy	0.0269	0.0394	CcSEcCtD
Etoricoxib—Drug eruption—Spironolactone—dilated cardiomyopathy	0.0159	0.0234	CcSEcCtD
Etoricoxib—Shoulder pain—Lisinopril—dilated cardiomyopathy	0.0149	0.0218	CcSEcCtD
Etoricoxib—Skin infection—Lisinopril—dilated cardiomyopathy	0.0133	0.0194	CcSEcCtD
Etoricoxib—Atrial flutter—Lisinopril—dilated cardiomyopathy	0.0105	0.0154	CcSEcCtD
Etoricoxib—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.0102	0.0149	CcSEcCtD
Etoricoxib—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00964	0.0141	CcSEcCtD
Etoricoxib—Drug eruption—Furosemide—dilated cardiomyopathy	0.00868	0.0127	CcSEcCtD
Etoricoxib—Bursitis—Lisinopril—dilated cardiomyopathy	0.00829	0.0121	CcSEcCtD
Etoricoxib—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00794	0.0116	CcSEcCtD
Etoricoxib—Nephritis interstitial—Furosemide—dilated cardiomyopathy	0.00791	0.0116	CcSEcCtD
Etoricoxib—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00697	0.0102	CcSEcCtD
Etoricoxib—Glycosuria—Furosemide—dilated cardiomyopathy	0.00659	0.00965	CcSEcCtD
Etoricoxib—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00651	0.00953	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00641	0.00939	CcSEcCtD
Etoricoxib—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00641	0.00939	CcSEcCtD
Etoricoxib—Gastritis—Spironolactone—dilated cardiomyopathy	0.0063	0.00923	CcSEcCtD
Etoricoxib—Heartburn—Lisinopril—dilated cardiomyopathy	0.00582	0.00852	CcSEcCtD
Etoricoxib—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00556	0.00814	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00544	0.00797	CcSEcCtD
Etoricoxib—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00544	0.00796	CcSEcCtD
Etoricoxib—Renal failure—Spironolactone—dilated cardiomyopathy	0.00539	0.0079	CcSEcCtD
Etoricoxib—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00532	0.00779	CcSEcCtD
Etoricoxib—Memory impairment—Lisinopril—dilated cardiomyopathy	0.0051	0.00747	CcSEcCtD
Etoricoxib—Bladder pain—Furosemide—dilated cardiomyopathy	0.00483	0.00707	CcSEcCtD
Etoricoxib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00466	0.00682	CcSEcCtD
Etoricoxib—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00456	0.00667	CcSEcCtD
Etoricoxib—Protein urine present—Lisinopril—dilated cardiomyopathy	0.0045	0.00658	CcSEcCtD
Etoricoxib—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00445	0.00652	CcSEcCtD
Etoricoxib—Alopecia—Spironolactone—dilated cardiomyopathy	0.00435	0.00637	CcSEcCtD
Etoricoxib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00412	0.00604	CcSEcCtD
Etoricoxib—Thirst—Furosemide—dilated cardiomyopathy	0.00407	0.00596	CcSEcCtD
Etoricoxib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00405	0.00593	CcSEcCtD
Etoricoxib—Neck pain—Lisinopril—dilated cardiomyopathy	0.00405	0.00593	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.004	0.00586	CcSEcCtD
Etoricoxib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00393	0.00576	CcSEcCtD
Etoricoxib—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00391	0.00573	CcSEcCtD
Etoricoxib—Cystitis—Lisinopril—dilated cardiomyopathy	0.00387	0.00566	CcSEcCtD
Etoricoxib—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00378	0.00554	CcSEcCtD
Etoricoxib—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00376	0.00551	CcSEcCtD
Etoricoxib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00363	0.00531	CcSEcCtD
Etoricoxib—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00362	0.0053	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00354	0.00518	CcSEcCtD
Etoricoxib—Confusional state—Spironolactone—dilated cardiomyopathy	0.00353	0.00517	CcSEcCtD
Etoricoxib—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.0035	0.00512	CcSEcCtD
Etoricoxib—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00349	0.00511	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00349	0.00511	CcSEcCtD
Etoricoxib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00343	0.00502	CcSEcCtD
Etoricoxib—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00342	0.005	CcSEcCtD
Etoricoxib—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00337	0.00494	CcSEcCtD
Etoricoxib—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00334	0.00489	CcSEcCtD
Etoricoxib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00328	0.00481	CcSEcCtD
Etoricoxib—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00328	0.0048	CcSEcCtD
Etoricoxib—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00323	0.00474	CcSEcCtD
Etoricoxib—Eczema—Lisinopril—dilated cardiomyopathy	0.00323	0.00474	CcSEcCtD
Etoricoxib—Injury—Lisinopril—dilated cardiomyopathy	0.00316	0.00463	CcSEcCtD
Etoricoxib—Somnolence—Spironolactone—dilated cardiomyopathy	0.00311	0.00456	CcSEcCtD
Etoricoxib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00307	0.00449	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00306	0.00448	CcSEcCtD
Etoricoxib—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00305	0.00447	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00302	0.00442	CcSEcCtD
Etoricoxib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00302	0.00442	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.003	0.0044	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00297	0.00434	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00296	0.00433	CcSEcCtD
Etoricoxib—Renal failure—Furosemide—dilated cardiomyopathy	0.00294	0.0043	CcSEcCtD
Etoricoxib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00291	0.00426	CcSEcCtD
Etoricoxib—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00288	0.00422	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00282	0.00413	CcSEcCtD
Etoricoxib—Urticaria—Spironolactone—dilated cardiomyopathy	0.00278	0.00407	CcSEcCtD
Etoricoxib—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00276	0.00405	CcSEcCtD
Etoricoxib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00272	0.00399	CcSEcCtD
Etoricoxib—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00266	0.00389	CcSEcCtD
Etoricoxib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00265	0.00388	CcSEcCtD
Etoricoxib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00263	0.00385	CcSEcCtD
Etoricoxib—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00263	0.00385	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00262	0.00383	CcSEcCtD
Etoricoxib—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00262	0.00383	CcSEcCtD
Etoricoxib—Visual impairment—Furosemide—dilated cardiomyopathy	0.00258	0.00378	CcSEcCtD
Etoricoxib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00258	0.00378	CcSEcCtD
Etoricoxib—Gastritis—Lisinopril—dilated cardiomyopathy	0.00257	0.00377	CcSEcCtD
Etoricoxib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00253	0.00371	CcSEcCtD
Etoricoxib—Eye disorder—Furosemide—dilated cardiomyopathy	0.0025	0.00367	CcSEcCtD
Etoricoxib—Tinnitus—Furosemide—dilated cardiomyopathy	0.0025	0.00366	CcSEcCtD
Etoricoxib—Pruritus—Spironolactone—dilated cardiomyopathy	0.00248	0.00363	CcSEcCtD
Etoricoxib—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00247	0.00362	CcSEcCtD
Etoricoxib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00246	0.00361	CcSEcCtD
Etoricoxib—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00245	0.00358	CcSEcCtD
Etoricoxib—Angiopathy—Furosemide—dilated cardiomyopathy	0.00243	0.00356	CcSEcCtD
Etoricoxib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00242	0.00354	CcSEcCtD
Etoricoxib—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00242	0.00354	CcSEcCtD
Etoricoxib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00239	0.00351	CcSEcCtD
Etoricoxib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00239	0.00351	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00234	0.00342	CcSEcCtD
Etoricoxib—Malnutrition—Furosemide—dilated cardiomyopathy	0.00233	0.00342	CcSEcCtD
Etoricoxib—Erythema—Furosemide—dilated cardiomyopathy	0.00233	0.00342	CcSEcCtD
Etoricoxib—Dizziness—Spironolactone—dilated cardiomyopathy	0.00231	0.00339	CcSEcCtD
Etoricoxib—Flatulence—Furosemide—dilated cardiomyopathy	0.0023	0.00337	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00229	0.00336	CcSEcCtD
Etoricoxib—Weight increased—Lisinopril—dilated cardiomyopathy	0.00229	0.00335	CcSEcCtD
Etoricoxib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00229	0.00335	CcSEcCtD
Etoricoxib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00227	0.00332	CcSEcCtD
Etoricoxib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00225	0.0033	CcSEcCtD
Etoricoxib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00224	0.00328	CcSEcCtD
Etoricoxib—Vomiting—Spironolactone—dilated cardiomyopathy	0.00223	0.00326	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00222	0.00325	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00221	0.00323	CcSEcCtD
Etoricoxib—Rash—Spironolactone—dilated cardiomyopathy	0.00221	0.00323	CcSEcCtD
Etoricoxib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0022	0.00323	CcSEcCtD
Etoricoxib—Renal failure—Lisinopril—dilated cardiomyopathy	0.0022	0.00322	CcSEcCtD
Etoricoxib—Vision blurred—Furosemide—dilated cardiomyopathy	0.0022	0.00322	CcSEcCtD
Etoricoxib—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.0022	0.00322	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.0022	0.00322	CcSEcCtD
Etoricoxib—Headache—Spironolactone—dilated cardiomyopathy	0.00219	0.00321	CcSEcCtD
Etoricoxib—Jaundice—Lisinopril—dilated cardiomyopathy	0.00218	0.0032	CcSEcCtD
Etoricoxib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00218	0.00319	CcSEcCtD
Etoricoxib—Anaemia—Furosemide—dilated cardiomyopathy	0.00216	0.00316	CcSEcCtD
Etoricoxib—Agitation—Furosemide—dilated cardiomyopathy	0.00214	0.00314	CcSEcCtD
Etoricoxib—Haematuria—Lisinopril—dilated cardiomyopathy	0.00214	0.00313	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00212	0.0031	CcSEcCtD
Etoricoxib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00211	0.00309	CcSEcCtD
Etoricoxib—Sinusitis—Lisinopril—dilated cardiomyopathy	0.0021	0.00308	CcSEcCtD
Etoricoxib—Nausea—Spironolactone—dilated cardiomyopathy	0.00208	0.00304	CcSEcCtD
Etoricoxib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00201	0.00294	CcSEcCtD
Etoricoxib—Hallucination—Lisinopril—dilated cardiomyopathy	0.002	0.00293	CcSEcCtD
Etoricoxib—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.002	0.00292	CcSEcCtD
Etoricoxib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00199	0.00291	CcSEcCtD
Etoricoxib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00198	0.0029	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00197	0.00289	CcSEcCtD
Etoricoxib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00197	0.00289	CcSEcCtD
Etoricoxib—Dry mouth—Furosemide—dilated cardiomyopathy	0.00194	0.00284	CcSEcCtD
Etoricoxib—Confusional state—Furosemide—dilated cardiomyopathy	0.00192	0.00281	CcSEcCtD
Etoricoxib—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.0019	0.00279	CcSEcCtD
Etoricoxib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.0019	0.00278	CcSEcCtD
Etoricoxib—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00188	0.00275	CcSEcCtD
Etoricoxib—Shock—Furosemide—dilated cardiomyopathy	0.00187	0.00274	CcSEcCtD
Etoricoxib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00187	0.00273	CcSEcCtD
Etoricoxib—Flushing—Lisinopril—dilated cardiomyopathy	0.00187	0.00273	CcSEcCtD
Etoricoxib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00186	0.00273	CcSEcCtD
Etoricoxib—Skin disorder—Furosemide—dilated cardiomyopathy	0.00185	0.00271	CcSEcCtD
Etoricoxib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00182	0.00267	CcSEcCtD
Etoricoxib—Anorexia—Furosemide—dilated cardiomyopathy	0.00182	0.00266	CcSEcCtD
Etoricoxib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00181	0.00265	CcSEcCtD
Etoricoxib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.0018	0.00263	CcSEcCtD
Etoricoxib—Alopecia—Lisinopril—dilated cardiomyopathy	0.00178	0.0026	CcSEcCtD
Etoricoxib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00176	0.00258	CcSEcCtD
Etoricoxib—Erythema—Lisinopril—dilated cardiomyopathy	0.00175	0.00256	CcSEcCtD
Etoricoxib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00175	0.00256	CcSEcCtD
Etoricoxib—Flatulence—Lisinopril—dilated cardiomyopathy	0.00173	0.00253	CcSEcCtD
Etoricoxib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00171	0.00251	CcSEcCtD
Etoricoxib—Somnolence—Furosemide—dilated cardiomyopathy	0.00169	0.00248	CcSEcCtD
Etoricoxib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00168	0.00246	CcSEcCtD
Etoricoxib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00166	0.00242	CcSEcCtD
Etoricoxib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00165	0.00242	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00164	0.00241	CcSEcCtD
Etoricoxib—Fatigue—Furosemide—dilated cardiomyopathy	0.00164	0.0024	CcSEcCtD
Etoricoxib—Tremor—Lisinopril—dilated cardiomyopathy	0.00164	0.0024	CcSEcCtD
Etoricoxib—Pain—Furosemide—dilated cardiomyopathy	0.00163	0.00238	CcSEcCtD
Etoricoxib—Constipation—Furosemide—dilated cardiomyopathy	0.00163	0.00238	CcSEcCtD
Etoricoxib—Anaemia—Lisinopril—dilated cardiomyopathy	0.00162	0.00237	CcSEcCtD
Etoricoxib—Angioedema—Lisinopril—dilated cardiomyopathy	0.0016	0.00234	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—ZIC3—dilated cardiomyopathy	0.0016	0.00569	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—ITGB1—dilated cardiomyopathy	0.00158	0.00562	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00157	0.0023	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00156	0.00228	CcSEcCtD
Etoricoxib—MAPK14—Kit receptor signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00156	0.00554	CbGpPWpGaD
Etoricoxib—Palpitations—Lisinopril—dilated cardiomyopathy	0.00155	0.00227	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—IL10—dilated cardiomyopathy	0.00154	0.00547	CbGpPWpGaD
Etoricoxib—Cough—Lisinopril—dilated cardiomyopathy	0.00153	0.00224	CcSEcCtD
Etoricoxib—Urticaria—Furosemide—dilated cardiomyopathy	0.00151	0.00222	CcSEcCtD
Etoricoxib—MAPK14—RAC1 signaling pathway—RAC1—dilated cardiomyopathy	0.00151	0.00537	CbGpPWpGaD
Etoricoxib—MAPK14—Interferon type I signaling pathways—RAC1—dilated cardiomyopathy	0.00151	0.00537	CbGpPWpGaD
Etoricoxib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00151	0.0022	CcSEcCtD
Etoricoxib—MAPK14—IL4-mediated signaling events—RPS6KB1—dilated cardiomyopathy	0.0015	0.00532	CbGpPWpGaD
Etoricoxib—Chest pain—Lisinopril—dilated cardiomyopathy	0.00149	0.00218	CcSEcCtD
Etoricoxib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00149	0.00218	CcSEcCtD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.00149	0.00529	CbGpPWpGaD
Etoricoxib—MAPK14—RANKL/RANK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00149	0.00529	CbGpPWpGaD
Etoricoxib—Anxiety—Lisinopril—dilated cardiomyopathy	0.00149	0.00217	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00148	0.00217	CcSEcCtD
Etoricoxib—MAPK14—IL12-mediated signaling events—FASLG—dilated cardiomyopathy	0.00147	0.00522	CbGpPWpGaD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—RAC1—dilated cardiomyopathy	0.00147	0.00522	CbGpPWpGaD
Etoricoxib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00146	0.00213	CcSEcCtD
Etoricoxib—MAPK14—Trk receptor signaling mediated by the MAPK pathway—RAF1—dilated cardiomyopathy	0.00145	0.00515	CbGpPWpGaD
Etoricoxib—MAPK14—Signalling to RAS—RAF1—dilated cardiomyopathy	0.00145	0.00515	CbGpPWpGaD
Etoricoxib—Confusional state—Lisinopril—dilated cardiomyopathy	0.00144	0.00211	CcSEcCtD
Etoricoxib—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00143	0.00209	CcSEcCtD
Etoricoxib—Oedema—Lisinopril—dilated cardiomyopathy	0.00143	0.00209	CcSEcCtD
Etoricoxib—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00143	0.00507	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00143	0.00507	CbGpPWpGaD
Etoricoxib—MAPK14—TSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00142	0.00506	CbGpPWpGaD
Etoricoxib—Infection—Lisinopril—dilated cardiomyopathy	0.00142	0.00208	CcSEcCtD
Etoricoxib—Shock—Lisinopril—dilated cardiomyopathy	0.00141	0.00206	CcSEcCtD
Etoricoxib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0014	0.00205	CcSEcCtD
Etoricoxib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.0014	0.00205	CcSEcCtD
Etoricoxib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00139	0.00203	CcSEcCtD
Etoricoxib—Asthenia—Furosemide—dilated cardiomyopathy	0.00137	0.002	CcSEcCtD
Etoricoxib—Anorexia—Lisinopril—dilated cardiomyopathy	0.00136	0.00199	CcSEcCtD
Etoricoxib—MAPK14—CDC42 signaling events—RPS6KB1—dilated cardiomyopathy	0.00136	0.00483	CbGpPWpGaD
Etoricoxib—Pruritus—Furosemide—dilated cardiomyopathy	0.00135	0.00197	CcSEcCtD
Etoricoxib—MAPK14—Endothelins—RAC1—dilated cardiomyopathy	0.00133	0.00475	CbGpPWpGaD
Etoricoxib—MAPK14—CXCR3-mediated signaling events—RAF1—dilated cardiomyopathy	0.00133	0.00472	CbGpPWpGaD
Etoricoxib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0013	0.00191	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0013	0.00191	CcSEcCtD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—GJA1—dilated cardiomyopathy	0.00129	0.0046	CbGpPWpGaD
Etoricoxib—Insomnia—Lisinopril—dilated cardiomyopathy	0.00129	0.00189	CcSEcCtD
Etoricoxib—MAPK14—AGE/RAGE pathway—RAC1—dilated cardiomyopathy	0.00129	0.00457	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00128	0.00457	CbGpPWpGaD
Etoricoxib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00127	0.00187	CcSEcCtD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—RAC1—dilated cardiomyopathy	0.00127	0.00452	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—RAC1—dilated cardiomyopathy	0.00127	0.00452	CbGpPWpGaD
Etoricoxib—Somnolence—Lisinopril—dilated cardiomyopathy	0.00127	0.00186	CcSEcCtD
Etoricoxib—Dizziness—Furosemide—dilated cardiomyopathy	0.00126	0.00184	CcSEcCtD
Etoricoxib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00126	0.00184	CcSEcCtD
Etoricoxib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00124	0.00182	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00123	0.00181	CcSEcCtD
Etoricoxib—Fatigue—Lisinopril—dilated cardiomyopathy	0.00123	0.0018	CcSEcCtD
Etoricoxib—MAPK14—CDC42 signaling events—RAC1—dilated cardiomyopathy	0.00123	0.00436	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—RAF1—dilated cardiomyopathy	0.00122	0.00435	CbGpPWpGaD
Etoricoxib—Pain—Lisinopril—dilated cardiomyopathy	0.00122	0.00179	CcSEcCtD
Etoricoxib—Constipation—Lisinopril—dilated cardiomyopathy	0.00122	0.00179	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00121	0.00431	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.00121	0.00431	CbGpPWpGaD
Etoricoxib—Vomiting—Furosemide—dilated cardiomyopathy	0.00121	0.00177	CcSEcCtD
Etoricoxib—Rash—Furosemide—dilated cardiomyopathy	0.0012	0.00176	CcSEcCtD
Etoricoxib—Dermatitis—Furosemide—dilated cardiomyopathy	0.0012	0.00176	CcSEcCtD
Etoricoxib—Headache—Furosemide—dilated cardiomyopathy	0.00119	0.00175	CcSEcCtD
Etoricoxib—MAPK14—Signalling to ERKs—RAF1—dilated cardiomyopathy	0.00118	0.00419	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00118	0.00172	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00117	0.00171	CcSEcCtD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.00116	0.00414	CbGpPWpGaD
Etoricoxib—MAPK14—Nanoparticle-mediated activation of receptor signaling—EGFR—dilated cardiomyopathy	0.00116	0.00413	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.00116	0.00413	CbGpPWpGaD
Etoricoxib—CYP2E1—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.00116	0.00411	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00115	0.00408	CbGpPWpGaD
Etoricoxib—MAPK14—p73 transcription factor network—FAS—dilated cardiomyopathy	0.00114	0.00404	CbGpPWpGaD
Etoricoxib—Urticaria—Lisinopril—dilated cardiomyopathy	0.00114	0.00166	CcSEcCtD
Etoricoxib—Nausea—Furosemide—dilated cardiomyopathy	0.00113	0.00166	CcSEcCtD
Etoricoxib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00113	0.00165	CcSEcCtD
Etoricoxib—PTGS2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00112	0.00397	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	0.00108	0.00386	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.00106	0.00377	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00105	0.00154	CcSEcCtD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—CD36—dilated cardiomyopathy	0.00103	0.00366	CbGpPWpGaD
Etoricoxib—Asthenia—Lisinopril—dilated cardiomyopathy	0.00103	0.0015	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—FAS—dilated cardiomyopathy	0.00102	0.00364	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.00101	0.0036	CbGpPWpGaD
Etoricoxib—Pruritus—Lisinopril—dilated cardiomyopathy	0.00101	0.00148	CcSEcCtD
Etoricoxib—MAPK14—IL2-mediated signaling events—RAF1—dilated cardiomyopathy	0.001	0.00356	CbGpPWpGaD
Etoricoxib—MAPK14—Monoamine Transport—TNF—dilated cardiomyopathy	0.000994	0.00353	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.000986	0.00351	CbGpPWpGaD
Etoricoxib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000978	0.00143	CcSEcCtD
Etoricoxib—PTGS2—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	0.000963	0.00343	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.000945	0.00336	CbGpPWpGaD
Etoricoxib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000945	0.00138	CcSEcCtD
Etoricoxib—MAPK14—Kit receptor signaling pathway—RAF1—dilated cardiomyopathy	0.000933	0.00332	CbGpPWpGaD
Etoricoxib—MAPK14—Cell-Cell communication—ITGB1—dilated cardiomyopathy	0.00093	0.00331	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—ITGB1—dilated cardiomyopathy	0.000919	0.00327	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.000911	0.00324	CbGpPWpGaD
Etoricoxib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000908	0.00133	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.000908	0.00323	CbGpPWpGaD
Etoricoxib—Rash—Lisinopril—dilated cardiomyopathy	0.000901	0.00132	CcSEcCtD
Etoricoxib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.0009	0.00132	CcSEcCtD
Etoricoxib—Headache—Lisinopril—dilated cardiomyopathy	0.000895	0.00131	CcSEcCtD
Etoricoxib—MAPK14—Activated TLR4 signalling—CD36—dilated cardiomyopathy	0.000887	0.00316	CbGpPWpGaD
Etoricoxib—MAPK14—Endothelins—RAF1—dilated cardiomyopathy	0.000885	0.00315	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—RAC1—dilated cardiomyopathy	0.000874	0.00311	CbGpPWpGaD
Etoricoxib—MAPK14—Amyotrophic lateral sclerosis (ALS)—TNF—dilated cardiomyopathy	0.000866	0.00308	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—RAF1—dilated cardiomyopathy	0.000863	0.00307	CbGpPWpGaD
Etoricoxib—MAPK14—TSH signaling pathway—RAF1—dilated cardiomyopathy	0.000853	0.00303	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—RAF1—dilated cardiomyopathy	0.000853	0.00303	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of retinoblastoma protein—RAF1—dilated cardiomyopathy	0.000853	0.00303	CbGpPWpGaD
Etoricoxib—Nausea—Lisinopril—dilated cardiomyopathy	0.000849	0.00124	CcSEcCtD
Etoricoxib—MAPK14—Hemostasis—TTN—dilated cardiomyopathy	0.000847	0.00301	CbGpPWpGaD
Etoricoxib—MAPK14—BCR signaling pathway—RAF1—dilated cardiomyopathy	0.000842	0.003	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—CD36—dilated cardiomyopathy	0.000835	0.00297	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling events mediated by VEGFR1 and VEGFR2—RAF1—dilated cardiomyopathy	0.000832	0.00296	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—RAC1—dilated cardiomyopathy	0.000825	0.00293	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.000823	0.00293	CbGpPWpGaD
Etoricoxib—MAPK14—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.000813	0.00289	CbGpPWpGaD
Etoricoxib—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000812	0.00289	CbGpPWpGaD
Etoricoxib—MAPK14—TWEAK Signaling Pathway—TNF—dilated cardiomyopathy	0.000799	0.00284	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.000791	0.00281	CbGpPWpGaD
Etoricoxib—MAPK14—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.00077	0.00274	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000762	0.00271	CbGpPWpGaD
Etoricoxib—MAPK14—Cell-Cell communication—RAC1—dilated cardiomyopathy	0.000748	0.00266	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000745	0.00265	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—CD36—dilated cardiomyopathy	0.000743	0.00264	CbGpPWpGaD
Etoricoxib—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00074	0.00263	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—RAC1—dilated cardiomyopathy	0.000738	0.00263	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ACTN2—dilated cardiomyopathy	0.000735	0.00261	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000727	0.00259	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000711	0.00253	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000709	0.00252	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000703	0.0025	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.000701	0.00249	CbGpPWpGaD
Etoricoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—TNF—dilated cardiomyopathy	0.000695	0.00247	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.000694	0.00247	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000692	0.00246	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000689	0.00245	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.000677	0.00241	CbGpPWpGaD
Etoricoxib—MAPK14—Thromboxane A2 receptor signaling—EGFR—dilated cardiomyopathy	0.000667	0.00237	CbGpPWpGaD
Etoricoxib—MAPK14—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000665	0.00237	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000658	0.00234	CbGpPWpGaD
Etoricoxib—MAPK14—Corticotropin-releasing hormone—RAF1—dilated cardiomyopathy	0.000654	0.00232	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00065	0.00231	CbGpPWpGaD
Etoricoxib—MAPK14—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.000644	0.00229	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000644	0.00229	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000633	0.00225	CbGpPWpGaD
Etoricoxib—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000632	0.00225	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000627	0.00223	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000627	0.00223	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—VCL—dilated cardiomyopathy	0.000625	0.00222	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000621	0.00221	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000609	0.00217	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000588	0.00209	CbGpPWpGaD
Etoricoxib—MAPK14—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000585	0.00208	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000581	0.00207	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.000579	0.00206	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—EGFR—dilated cardiomyopathy	0.000578	0.00205	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00056	0.00199	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000549	0.00195	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000547	0.00194	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000519	0.00185	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000516	0.00184	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000511	0.00182	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000502	0.00179	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000499	0.00177	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—RAF1—dilated cardiomyopathy	0.00049	0.00174	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.000489	0.00174	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000484	0.00172	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000475	0.00169	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000472	0.00168	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000462	0.00164	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000459	0.00163	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000458	0.00163	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000457	0.00162	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	0.000444	0.00158	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000431	0.00153	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—NR3C2—dilated cardiomyopathy	0.00043	0.00153	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—RAF1—dilated cardiomyopathy	0.00042	0.00149	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000416	0.00148	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000411	0.00146	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000404	0.00144	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000398	0.00141	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000393	0.0014	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000391	0.00139	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000371	0.00132	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000368	0.00131	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000364	0.0013	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000358	0.00127	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000351	0.00125	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000343	0.00122	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000324	0.00115	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—ITGB1—dilated cardiomyopathy	0.00032	0.00114	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ITGB1—dilated cardiomyopathy	0.000314	0.00112	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000308	0.0011	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000307	0.00109	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	0.00029	0.00103	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	0.00029	0.00103	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000285	0.00101	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.000283	0.00101	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000282	0.001	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000282	0.001	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.000277	0.000985	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CD36—dilated cardiomyopathy	0.000273	0.00097	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	0.000273	0.000969	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—NPPA—dilated cardiomyopathy	0.00027	0.00096	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000269	0.000956	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000269	0.000956	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—CD36—dilated cardiomyopathy	0.000267	0.000951	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000264	0.000938	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000264	0.000938	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	0.000262	0.000931	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—RAC1—dilated cardiomyopathy	0.000257	0.000914	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—RAC1—dilated cardiomyopathy	0.000252	0.000896	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00025	0.000889	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	0.000246	0.000877	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CD36—dilated cardiomyopathy	0.000241	0.000856	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000238	0.000846	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000235	0.000837	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000235	0.000835	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000233	0.000828	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—RAC1—dilated cardiomyopathy	0.000227	0.000807	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000224	0.000796	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000223	0.000795	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.00021	0.000748	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000206	0.000732	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000204	0.000725	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000193	0.000688	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000192	0.000682	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.00019	0.000676	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000181	0.000643	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000175	0.000622	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000174	0.00062	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000173	0.000617	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—RAF1—dilated cardiomyopathy	0.00017	0.000606	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00017	0.000604	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—RAF1—dilated cardiomyopathy	0.000167	0.000594	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ITGB1—dilated cardiomyopathy	0.000164	0.000585	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000164	0.000583	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NPPA—dilated cardiomyopathy	0.00016	0.000569	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.00016	0.000568	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00016	0.000568	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000156	0.000553	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PSEN2—dilated cardiomyopathy	0.000155	0.000551	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000152	0.000541	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000151	0.000537	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000151	0.000537	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—RAF1—dilated cardiomyopathy	0.00015	0.000535	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000148	0.000527	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00014	0.000499	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD36—dilated cardiomyopathy	0.00014	0.000499	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.00014	0.000498	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000136	0.000483	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000134	0.000478	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—RAC1—dilated cardiomyopathy	0.000132	0.00047	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000126	0.00045	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—dilated cardiomyopathy	0.000117	0.000416	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000116	0.000413	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000116	0.000413	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000114	0.000407	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000113	0.000402	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TNF—dilated cardiomyopathy	0.000111	0.000396	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00011	0.000391	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000106	0.000376	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—dilated cardiomyopathy	0.000103	0.000367	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000103	0.000366	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000102	0.000362	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.46e-05	0.000336	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.27e-05	0.00033	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.04e-05	0.000321	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.8e-05	0.000313	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—RAF1—dilated cardiomyopathy	8.76e-05	0.000312	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RAC1—dilated cardiomyopathy	8.54e-05	0.000304	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AGT—dilated cardiomyopathy	8.16e-05	0.00029	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	7.93e-05	0.000282	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RAC1—dilated cardiomyopathy	7.8e-05	0.000277	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	7.11e-05	0.000253	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CD36—dilated cardiomyopathy	6.93e-05	0.000246	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	6.7e-05	0.000238	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	6.52e-05	0.000232	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AGT—dilated cardiomyopathy	6.24e-05	0.000222	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—dilated cardiomyopathy	6.01e-05	0.000214	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	5.87e-05	0.000209	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—RAF1—dilated cardiomyopathy	5.67e-05	0.000202	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—RAF1—dilated cardiomyopathy	5.17e-05	0.000184	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	5.17e-05	0.000184	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	5.03e-05	0.000179	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	4.75e-05	0.000169	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.71e-05	0.000168	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	4.63e-05	0.000165	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.59e-05	0.000163	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	4.53e-05	0.000161	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.17e-05	0.000148	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.13e-05	0.000147	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	4.03e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.92e-05	0.000139	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—dilated cardiomyopathy	3.89e-05	0.000138	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—dilated cardiomyopathy	3.54e-05	0.000126	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.53e-05	0.000126	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.11e-05	0.00011	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.03e-05	0.000108	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.72e-05	9.69e-05	CbGpPWpGaD
